A-3.4. Disclosure and Management Strategies

  1. Each Board member or a person under consideration for appointment to the Board must disclose any apparent or potential conflict of interest and take affirmative steps to mitigate the effect of each conflict of interest.
    1. Each Board member or a person under consideration for appointment to the Board must disclose:
      1. Any new or existing contractual or financial relationships with a company, ownership or investment or financial interests, or other interests in a manufacturer/labeler or PBM that the Board member, family member, or relative holds or acquires during the board member's tenure on the DUR Board or was held or acquired within the two years immediately preceding the Board member's appointment;
      2. Any financial interests in an actual or proposed transaction or arrangement that may be of some business interest to HHSC or its affiliated organizations;
      3. Any direct or indirect payments, gifts, compensation, royalties, rewards, or other goods or services valued at over $500 from a manufacturer/labeler with a financial interest in the outcome of a matter; and
      4. Other interests conflicting or interfering with the Board member's ability to perform their duties while serving on the Board.
    2. Each Board member or a person under consideration for appointment to the Board must:
      1. Complete and submit to HHSC the Texas Vendor Drug Program Drug Utilization Review Board Annual Disclosure form within 30 days after appointment to the Board and at the first Board meeting of each State Fiscal Year (Sept.-Aug.) while serving on the Board.
      2. Complete and submit to HHSC the DSHS Services Continuing Education Service Disclosure of Financial Interests form within 30 days after appointment to the Board and at the first Board meeting of each State Fiscal Year while serving on the Board.
      3. Complete and submit to HHSC the Statement by Members form within 30 days after appointment to the Board and after each amendment to the Texas DUR Board Bylaws while serving on the Board.
      4. Attend an in-person Ethics and Conflict of Interest training delivered by the HHS Ethics Office during the orientation session before a new Board member's first official DUR Board meeting and every two years thereafter while serving on the Board.
      5. Notify HHSC in writing within 15 business days of any changes in the Board member's status that may cause or have the appearance of a potential or actual conflict of interest while serving on the Board.
    3. HHSC will publish the Drug Utilization Review Board Annual Disclosure (HHS Form 1349) completed by each Board member at the first Board meeting of each state fiscal year. The forms will appear on the Texas Vendor Drug Program website. HHSC will publish and retain the forms per HHSC records management policies.